Panel wants regulations for genetic tests

Jan 18, 2008

A federal panel contended that regulations for genetic testing have not advanced with the growing number of consumers who buy them.

The panel, named the Secretary's Advisory Committee on Genetics, Health and Society, argued that the increasing amount of genetic trials have been advertised with unproved claims and could be deceptive, The New York Times reported Friday. The panel is part of the Department of Health and Human Services.

Cancer, diabetes, heart failure, and cystic fibrosis are among the conditions the tests claim to inform at risk patients of.

The panel warns that inaccurate test results given by doctors who lack experience with them could cause harm to sick patients in need of correct treatment.

"We would welcome more federal regulation. It's unclear what regulatory requirements apply to our products," Sciona Chief Science Officer, Rosalynn D. Gill said of the company, which conducts "nutrigenetic tests" over the internet.

The panel wrote in a report that test providers lack requirements for information disclosure to support their claims and that proof of their value is rare.

Copyright 2008 by United Press International

Explore further: Cardinal Health paying $26.8 million in FTC settlement

Related Stories

Google's moonshots, gender bias at South by Southwest

Mar 18, 2015

Music flooded into the streets around Austin's convention center as South by Southwest's music festival kicked off and the interactive portion wrapped up. The head of Google's (X) division talked about testing ...

RCas9: A programmable RNA editing tool

Oct 03, 2014

A powerful scientific tool for editing the DNA instructions in a genome can now also be applied to RNA, the molecule that translates DNA's genetic instructions into the production of proteins. A team of researchers ...

Seeds to skyscrapers

Jun 25, 2014

Wood is one of the oldest building materials but its use is limited by its properties. With new funding, researchers aim to stretch these properties to an unprecedented degree, creating the means to build ...

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

18 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.